- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Détention brevets de la classe C07K 14/705
Brevets de cette classe: 15772
Historique des publications depuis 10 ans
|
925
|
1166
|
1288
|
1385
|
1569
|
1544
|
1455
|
1362
|
1173
|
689
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20790 |
342 |
| The Trustees of the University of Pennsylvania | 4416 |
332 |
| The Board of Trustees of the Leland Stanford Junior University | 6668 |
215 |
| Regeneron Pharmaceuticals, Inc. | 4741 |
202 |
| Memorial Sloan-Kettering Cancer Center | 2048 |
200 |
| Board of Regents, The University of Texas System | 6127 |
169 |
| Novartis AG | 10224 |
147 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3002 |
147 |
| Immatics Biotechnologies GmbH | 1126 |
140 |
| The General Hospital Corporation | 4870 |
98 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
92 |
| Autolus Limited | 266 |
85 |
| City of Hope | 1038 |
85 |
| Alpine Immune Sciences, Inc. | 87 |
82 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1027 |
78 |
| Baylor College of Medicine | 1009 |
76 |
| CRISPR Therapeutics AG | 366 |
73 |
| Lentigen Technology, Inc. | 107 |
72 |
| The Johns Hopkins University | 5898 |
71 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3331 |
71 |
| Autres propriétaires | 12995 |